Commentary: H. pylori eradication therapy after subtotal gastrectomy for gastric cancer - can the qualitative be quantified?

Genta, R M

Genta, R M.

Affiliation

Genta RM; Miraca Life Sciences Research Institute, Miraca Life Sciences, Irving, TX, USA; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA. robert.genta@utsouthwestern.edu.

Aliment Pharmacol Ther ; 38(8): 989-90, 2013 Oct.

Article in En | MEDLINE | ID: mdl-24074309

Subject(s)

Adenocarcinoma/surgery; Anti-Bacterial Agents/therapeutic use; Helicobacter Infections/drug therapy; Helicobacter pylori/drug effects; Intestines/pathology; Proton Pump Inhibitors/therapeutic use; Stomach Neoplasms/surgery; Stomach/pathology; Female; Humans; Male

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stomach / Stomach Neoplasms / Adenocarcinoma / Helicobacter pylori / Helicobacter Infections / Proton Pump Inhibitors / Intestines / Anti-Bacterial Agents Type of study: Qualitative_research Limits: Female / Humans / Male Language: En Journal: Aliment Pharmacol Ther Year: 2013 Document type: Article

Fulltext

XML

PubMed Links

Search on Google